Published in Med Oncol on July 07, 2011
Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol (2012) 1.19
Sunitinib re-challenge in advanced renal-cell carcinoma. Br J Cancer (2014) 0.93
Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization. J Cell Mol Med (2014) 0.86
Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man-PFS2: A Measure of Therapeutic Action-At-A-Distance. Neoplasia (2015) 0.83
Kinome expression profiling identifies IKBKE as a predictor of overall survival in clear cell renal cell carcinoma patients. Carcinogenesis (2012) 0.83
A streamlined search technology for identification of synergistic drug combinations. Sci Rep (2015) 0.81
Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. Immunotargets Ther (2013) 0.79
Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranib. Can Urol Assoc J (2014) 0.75
More than 10 years survival with sequential therapy in a patient with advanced renal cell carcinoma: a case report. Braz J Med Biol Res (2014) 0.75
Metastatic renal cell carcinoma change vascularity. Case Rep Urol (2012) 0.75
Axitinib in metastatic renal cell carcinoma: single center experience. Contemp Oncol (Pozn) (2017) 0.75
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
Overview of the main outcomes in breast-cancer prevention trials. Lancet (2003) 4.31
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res (2000) 3.95
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res (2001) 3.55
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet (2015) 2.70
Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Oncol (2014) 2.29
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res (2001) 2.29
Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. BJOG (2012) 2.14
A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer (2006) 1.85
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res (2000) 1.82
Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res (1989) 1.82
A high incidence of vertebral fracture in women with breast cancer. Br J Cancer (1999) 1.74
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res (1999) 1.66
Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology (2000) 1.64
Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer (2008) 1.62
Cerebral venous thrombosis in adults. A study of 40 cases from Saudi Arabia. Stroke (1995) 1.58
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res (1998) 1.54
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol (2007) 1.52
Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood (2000) 1.52
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol (2000) 1.51
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer (2006) 1.42
Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation. Breast (2004) 1.42
Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone (1996) 1.38
Review of a hospital experience of breast abscesses. Br J Surg (1989) 1.38
Tuberculous spondylitis: analysis of 69 cases from Saudi Arabia. Spine (Phila Pa 1976) (2001) 1.30
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol (2005) 1.24
Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene (2010) 1.24
British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med (2008) 1.23
The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer. Endocr Relat Cancer (2000) 1.22
Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol (2011) 1.19
Acute hepatitis B after autologous stem cell transplantation in a man previously infected by hepatitis B virus. Bone Marrow Transplant (1999) 1.19
Spectrum of clinical variability in familial deletion 22q11.2: from full manifestation to extremely mild clinical anomalies. Clin Genet (2003) 1.18
Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol (2006) 1.17
A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol. Br J Cancer (2011) 1.17
Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol (1994) 1.16
A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. Br J Cancer (2008) 1.15
Proteomic study of salivary peptides and proteins in patients with Sjögren's syndrome before and after pilocarpine treatment. Arthritis Rheum (2007) 1.14
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst (1996) 1.13
Current management of ovarian carcinosarcoma. Int J Gynecol Cancer (2007) 1.13
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Eur J Cancer (2011) 1.13
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol (2009) 1.12
The prevalence of epilepsy and other seizure disorders in an Arab population: a community-based study. Seizure (2001) 1.10
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer (2006) 1.09
Preoperative embolization in surgical treatment of mediastinal hemangiopericytoma. Ann Thorac Surg (2000) 1.08
Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. J Biol Chem (1997) 1.08
Low-dose induction chemotherapy with Baby-BOP in patients with metastatic germ-cell tumours does not compromise outcome: a single-centre experience. Ann Oncol (2010) 1.07
Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer (2013) 1.06
Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study. Ann Oncol (2004) 1.04
Mortality of plastic-ware workers exposed to radiofrequencies. Bioelectromagnetics (1997) 1.04
Update of the follow-up of mortality and cancer incidence among European workers employed in the vinyl chloride industry. Epidemiology (2001) 1.03
A community survey of neurological disorders in Saudi Arabia: the Thugbah study. Neuroepidemiology (1993) 1.03
The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res (2002) 1.02
[Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines]. Actas Urol Esp (2012) 1.02
The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment Pharmacol Ther (2005) 1.02
Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res (2000) 1.02
Selective modulation of protein kinase isozymes by the site-selective analog 8-chloroadenosine 3',5'-cyclic monophosphate provides a biological means for control of human colon cancer cell growth. Proc Natl Acad Sci U S A (1988) 1.02
Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol (2003) 1.01
The role of imaging in staging and monitoring testicular cancer. Diagn Interv Imaging (2012) 1.01
Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. Ann Oncol (2011) 1.00
Cerebral palsy in Saudi Arabia: a case-control study of risk factors. Dev Med Child Neurol (1991) 1.00
Cripto-1 induces phosphatidylinositol 3'-kinase-dependent phosphorylation of AKT and glycogen synthase kinase 3beta in human cervical carcinoma cells. Cancer Res (1999) 1.00
Mortality study of workers employed by the Italian National Institute of Health, 1960-1989. Scand J Work Environ Health (1992) 0.99
Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues. Int J Cancer (1996) 0.99
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant (2006) 0.99
Epilepsy and other convulsive disorders in Saudi Arabia: a prospective study of 1,000 consecutive cases. Acta Neurol Scand (1990) 0.98
Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer (2003) 0.98
Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy. Br J Cancer (2006) 0.97
Cancer risk among female agricultural workers: a multi-center case-control study. Am J Ind Med (1999) 0.97
An antisense oligodeoxynucleotide that depletes RI alpha subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res (1993) 0.97
Type of estrogen receptor determines response to antiestrogen therapy. Cancer Res (1996) 0.97
RAS transformation causes sustained activation of epidermal growth factor receptor and elevation of mitogen-activated protein kinase in human mammary epithelial cells. Int J Cancer (2000) 0.97
Stroke in a Saudi Arabian National Guard community. Analysis of 500 consecutive cases from a population-based hospital. Stroke (1993) 0.97
Cripto-1 indirectly stimulates the tyrosine phosphorylation of erb B-4 through a novel receptor. J Biol Chem (1999) 0.97
High serum galectin-3 in advanced melanoma: preliminary results. Clin Exp Dermatol (2006) 0.97
Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 0.97
Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. Gynecol Oncol (2004) 0.96
EUROPLAN: a project to support the development of national plans on rare diseases in Europe. Public Health Genomics (2014) 0.96
Interactions between the epidermal growth factor receptor and type I protein kinase A: biological significance and therapeutic implications. Clin Cancer Res (1998) 0.96
Septic sacroiliitis: an uncommon septic arthritis. Clin Exp Rheumatol (2010) 0.96
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer (1999) 0.96
Development and use of a natural history data base of breast cancer studies. Am J Clin Oncol (1987) 0.95
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol (2011) 0.95
Molecular profiling of head and neck tumors. Curr Opin Oncol (2004) 0.95
Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency. Ann Rheum Dis (2007) 0.95
Site-selective cyclic AMP analogs provide a new approach in the control of cancer cell growth. FEBS Lett (1987) 0.94
Inhibition of growth and modulation of gene expression in human lung carcinoma in athymic mice by site-selective 8-Cl-cyclic adenosine monophosphate. Cancer Res (1989) 0.94
Expression of Wnt5a is downregulated by extracellular matrix and mutated c-Ha-ras in the human mammary epithelial cell line MCF-10A. Biochem Biophys Res Commun (1997) 0.94
Stroke register: experience from the eastern province of Saudi Arabia. Cerebrovasc Dis (1998) 0.94
Cripto: a novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia. Bioessays (1999) 0.93
Transvaginal ultrasound studies of vascular and morphological changes in uteri exposed to diethylstilbestrol in utero. Hum Reprod (1996) 0.93
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol (2001) 0.93
Synergistic effects in sonochemical sterilization. Appl Microbiol (1967) 0.93
[Pneumorachis associated with spontaneous pneumomediastinum. A case report]. Radiol Med (1997) 0.93
Asbestos-related lung cancer mortality in Piedmont, Italy. Am J Ind Med (1998) 0.93
The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br J Cancer (1991) 0.93
8-Chloro-cyclic AMP inhibits autocrine and angiogenic growth factor production in human colorectal and breast cancer. Clin Cancer Res (1997) 0.92